Relapsed/refractory B-cell lymphoma
Clinical trials for Relapsed/refractory B-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory B-cell lymphoma trials appear
Sign up with your email to follow new studies for Relapsed/refractory B-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells with an emergency brake tested in lymphoma
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Promising CAR-T trial for blood cancer withdrawn before starting
Disease control CancelledThis study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the tri…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase 1 • Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC